Michael D. Wyatt

Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy

This study develops and characterizes abbapolins, non-peptidic PLK1 PBD inhibitors, showing in vivo efficacy against prostate cancer and synergy with enzalutamide.

AI-based mining of biomedical literature: Applications for drug repurposing for the treatment of dementia

This paper introduces AGATHA, an AI tool for drug repurposing in dementia by analyzing biomedical literature and identifying gene-disease associations using statistical methods.

Insights into the Structural Regulation of Polo-Like Kinase Activity using AlphaFold

This paper uses AlphaFold to analyze the structural regulation of Polo-Like Kinase (PLK) activity, revealing domain arrangements and interactions that explain activity regulation and phosphopeptide selectivity.

Collateral damage of NUDT15 deficiency in cancer provides a cancer pharmacogenetic therapeutic window with thiopurines

The paper identifies that NUDT15 loss in cancer cells creates a therapeutic window for thiopurines, showing increased sensitivity in cancer cell lines and reduced prostate cancer incidence with thiopurine and xanthine oxidase inhibitor co-treatment.

Suppression of HIV and cocaine-induced neurotoxicity and inflammation by cell penetrable itaconate esters

This paper shows that 4-octyl-itaconate reduces HIV and cocaine-induced neurotoxicity and inflammation by modulating microglial activity and anti-inflammatory pathways.

Inhibition of the Dead Box RNA Helicase 3 prevents HIV-1 Tat and cocaine-induced neurotoxicity by targeting microglia activation

This study identifies DDX3 inhibition as a potential therapy for HAND by blocking Tat and cocaine-induced microglial activation and neurotoxicity in rat and mouse models.